newsfilter
← Latest News
GlobeNewswire·

Arvinas to Present at Jefferies Global Healthcare Conference

  • Arvinas Inc. management will participate in a fireside chat at the Jefferies Global Healthcare Conference on November 18 at 9:00 a.m. GMT/4:00 a.m. EST.
  • A live audio webcast of the event will be available via the provided link & the "Events and Presentations" section of the company website.
  • Arvinas utilizes its PROTAC protein degrader platform to develop therapies that remove disease-causing proteins.
  • The company's first FDA-approved PROTAC, developed with Pfizer, is exclusively outlicensed to Rigel Pharmaceuticals for global development, manufacturing, & commercialization.
  • Current clinical programs include ARV-393 for non-Hodgkin Lymphoma, ARV-102 for neurodegenerative disorders, ARV-027 for spinal-bulbar muscular atrophy, & ARV-6723 for advanced solid tumors.
  • ARV-806, targeting KRAS G12D for solid tumors, has advanced to the clinic, with plans announced to seek an out-licensing agreement for future trials.
  • Arvinas is headquartered in New Haven, Connecticut.
Company
Arvinas Inc.
Keywords
Nasdaq:ARVN, Arvinas Inc., ARVN, Arvinas, PROTAC